Lysogene Reports its Cash Position as of 31 December 2020
17 Febbraio 2021 - 08:00AM
Business Wire
- Cash and cash equivalents of €18.8 million1 as of 31
December 2020
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS), a phase 3 gene
therapy platform Company targeting central nervous system (CNS)
diseases, today reports its cash position as of 31 December
2020.
As of 31 December 2020, cash and cash equivalents amounted to
€18.8 million1 (compared to €22.1 million as of 30 September
2020).
"Thanks to a stringent cash management and a recently announced
€5 million state-guaranteed loan, our cash runway is extended
through Q2 2022. We will actively prepare the initiation of our
second clinical program with LYS-GM101 in GM1 gangliosidosis while
continuing to invest in our early-stage programs", said Stéphane
Durant des Aulnois, Chief Financial Officer of Lysogene.
About Lysogene
Lysogene is a gene therapy Company focused on the treatment of
orphan diseases of the central nervous system (CNS). The Company
has built a unique capability to enable a delivery of gene
therapies to the CNS to treat lysosomal diseases and other genetic
disorders of the CNS. A phase 2/3 clinical trial in MPS IIIA in
partnership with Sarepta Therapeutics, Inc. is ongoing. An adaptive
clinical trial in GM1 gangliosidosis is in preparation. In
accordance with the agreements signed between Lysogene and Sarepta
Therapeutics, Inc., Sarepta Therapeutics, Inc. will hold exclusive
commercial rights to LYS-SAF302 in the United States and markets
outside Europe; and Lysogene will maintain commercial exclusivity
of LYS-SAF302 in Europe. Lysogene is also collaborating with an
academic partner to define the strategy of development for the
treatment of Fragile X syndrome, a genetic disease related to
autism. www.lysogene.com.
Forward Looking Statement
This press release may contain certain forward-looking
statements, especially on the Company’s progress of its clinical
trials and cash runway. Although the Company believes its
expectations are based on reasonable assumptions, all statements
other than statements of historical fact included in this press
release about future events are subject to (i) change without
notice, (ii) factors beyond the Company’s control, (iii) clinical
trial results, (iv) increased manufacturing costs and (v) potential
claims on its products. These statements may include, without
limitation, any statements preceded by, followed by or including
words such as “target,” “believe,” “expect,” “aim,” “intend,”
“may,” “anticipate,” “estimate,” “plan,” “objective”, “project,”
“will,” “can have,” “likely,” “should,” “would,” “could” and other
words and terms of similar meaning or the negative thereof.
Forward-looking statements are subject to inherent risks and
uncertainties beyond the Company’s control that could cause the
Company’s actual results, performance or achievements to be
materially different from the expected results, performance or
achievements expressed or implied by such forward-looking
statements. A further list and description of these risks,
uncertainties and other risks can be found in the Company’s
regulatory filings with the French Autorité des Marchés Financiers,
including in the 2019 universal registration document, registered
with the French Markets Authorities on April 30, 2020, under number
D.20-0427, and future filings and reports by the Company.
Furthermore, these forward-looking statements are only as of the
date of this press release. Readers are cautioned not to place
undue reliance on these forward-looking statements. Except as
required by law, the Company assumes no obligation to update these
forward-looking statements publicly, or to update the reasons
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future. If the Company updates one or more
forward-looking statements, no inference should be drawn that it
will or will not make additional updates with respect to those or
other forward-looking statements.
This press release has been prepared in both French and English.
In the event of any differences between the two texts, the French
language version shall supersede.
1 Unaudited figure
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210216005651/en/
Stéphane Durant des Aulnois Chief Financial Officer stephane.durant-des-aulnois@lysogene.com + 33 1 41
43 03 99